Related Experiment Video
Updated: Aug 11, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Surgical neoadjuvant chemo-hormonal therapy for advanced prostatic carcinoma]
M Maruoka1, Y Nishikawa, T Miyauchi
1Department of Urology, Chiba Cancer Center Hospital.
Hinyokika Kiyo. Acta Urologica Japonica
|July 1, 1994
Summary
This study combined surgery with chemo-hormonal therapy for advanced prostate cancer. The treatment improved survival and quality of life for patients with stage D2 prostate carcinoma.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Context:
- Advanced prostate carcinoma (stage D2) presents significant challenges.
- Infiltration of adjacent organs and severe symptoms like hematuria and ileus require aggressive treatment.
Purpose:
- To evaluate the efficacy of combined surgical treatment and chemo-hormonal therapy.
- To improve therapeutic outcomes and quality of life (QOL) in patients with advanced prostate carcinoma.
Summary:
- Twelve patients with stage D2 prostate carcinoma underwent either total cystprostatectomy or pelvic exenteration combined with chemo-hormonal therapy.
- Treatment involved etoposide and diethylbestrol diphosphate pre- and post-operatively, with maintenance therapy.
- Eight patients had cystprostatectomy, and four had pelvic exenteration; all underwent urinary diversion and lymph node dissection.
Impact:
- Nine out of twelve patients survived, with notable complete and partial responses observed.
- The combined approach demonstrated effectiveness in both therapeutic results and enhancing patient QOL.
- This strategy offers a valuable option for managing advanced prostate carcinoma.
